(RTTNews) - THL Partners, Thursday announced an agreement to Headlands Research, a multinational network of clinical trial sites, from funds managed by KKR & Co. Inc. (KKR).
The deal is expected to boost Headlands' continued expansion, enhance its technology and centralized infrastructure, and further strengthen its ability to deliver high-quality, diverse clinical trial data for pharmaceutical and biotech sponsors.
THL will finance the deal, expected to close this year, with its flagship Fund IX.
Currently, KKR is trading at $146.40, down 0.81 percent on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
